Tristel PLC on Monday said it was granted approval from the US Food & Drug Administration for its ultrasound disinfectant for immediate sale.

Shares in Tristel were up 15% at 417.11 pence each in London on Monday morning.

The Cambridgeshire-based maker of infection prevention said its Tristel Ult disinfectant gel, which is used on endocavity ultrasound probes and skin surface transducers, will be its second product to be approved in the US, and will be launched in October.

Tristel Ult will be manufactured by Parker Laboratories Inc in New Jersey.

Back in July, Tristel submitted its request for approval to the FDA for Tristel Ult.

Tristel had made its entry into the US market with its foam-based disinfectant for surfaces Tristel Duo, which was approved by the US Environmental Protection Agency last year.

The company also announced on Monday that Tristel Duo is now registered in all states of the US. The company said the ‘milestone achievement’ will increase Tristel’s global revenue and profit.

Chief Executive Officer Paul Swinney said: ‘This FDA approval enables our full-blown entry into the United States ultrasound market and is a significant inflection point for the company. We will now be present in the single largest ultrasound market in the world.’

Copyright 2023 Alliance News Ltd. All Rights Reserved.